USA flag logo/image

An Official Website of the United States Government

Therapeutic miRNAs in combination with conventional chemotherapy

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43CA165450
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
PA11-096
Small Business Information
MIRNA THERAPEUTICS, INC.
2150 WOODWARD ST AUSTIN, TX 78744-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Therapeutic miRNAs in combination with conventional chemotherapy
Agency: HHS
Contract: 1R43CA165450-01A1
Award Amount: $299,999.00
 

Abstract:

DESCRIPTION (provided by applicant): Mirna Therapeutics, a Texas-based company, is developing non-small cell lung cancer (NSCLC) therapies using tumor suppressor miRNAs. This approach, miRNA replacement therapy , is based on the concept that re-introduction of miRNAs depleted in cancer cells reactivates cellular pathways that drive a therapeutic response. Mirna is developing 5 miRNA candidates and has extensive data showing that therapeutic delivery of miRNAs mimics robustly inhibits tumor growth and iswell tolerated in pre-clinical animal studies. In agreement with preliminary data, we hypothesize that miRNAs will sensitize cancer cells to conventional therapies which will generate more efficacious cancer treatments with minimal toxicity in normal tissues. In this proposal, we seek to systematically evaluate the combinatorial effects of miRNA mimics and conventional therapies that are most commonly used in the clinic today. The studies will feature the chemotherapeutic agents cisplatin, carboplatin, gemcitabine and paclitaxel, as well as 5 mimics of the most efficacious tumor suppressors that Mirna has identified over the course of an 8-year research program using cell and animal models of cancer and are now part of its pipeline for therapeutic development. A key strength of this proposal is access to lung cancer cell lines for which sensitivity and resistance to conventional therapies are well documented. In Aim 1, miRNA/chemo combinations will be evaluated using cancer cells that are either sensitive orresistant to the individual chemotherapy to identify those that are more effective than chemo alone. In Aim 2, the 1-2 most effective miRNA/chemo combos will be evaluated in the animal models of cancer. The goal of this proposal is to identify a miRNA/chemo combination with improved efficacy for further clinical development. PUBLIC HEALTH RELEVANCE: Combinatorial therapy is broadly viewed as the most effective way to treat cancer. Using models of lung cancer, this proposal seeks to evaluate the combination of conventional chemotherapies with therapeutic miRNAs, a promising class of anti-cancer agents. The goal is to identify a miRNA/chemo combination that is more effective than chemotherapy alone.

Principal Investigator:

Andreas G. Bader
512-681-5367
abader@mirnarx.com

Business Contact:

Annette Schlageter
512-681-5367
aschlageter@asuragen.com
Small Business Information at Submission:

MIRNA THERAPEUTICS, INC.
2150 WOODWARD ST AUSTIN, TX 78744-

EIN/Tax ID: 126182480
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No